| Bioactivity | C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model[1]. |
| Invitro | C105SR (0.5/1/5/10/50/100 μM) 抑制线粒体 CypD PPIase 活性[1]。 C105SR (1μM, 4 h for hypoxia (1% O2) plus 1 h for reoxygenation (21% O2)) 可阻止 mPTP 开放[1]。 C105SR (0.5/1/5/10/50/100 μM, 4 h for hypoxia (1% O2) 减少了缺氧/复氧诱导的 AML-12 细胞死亡[1]。 0 --> C105SR 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | C105SR (50 mg/kg, Subcutaneous injection (s.c.), 24 h before ischaemia–reperfusion injury (IRI) surgical procedure, single dose) 在肝脏缺血再灌注损伤小鼠模型中有保护作用[1]。 Animal Model: |
| Name | C105SR |
| Formula | C32H33BrN4O3S |
| Molar Mass | 633.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kheyar A, et al. The novel cyclophilin inhibitor C105SR reduces hepatic ischaemia–reperfusion injury via mitoprotection [J]. JHEP Reports, 2023, 5(11): 100876. |